{
  "query": "company name regulatory penalties",
  "timestamp": "2025-09-06 08:05:28",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "rt / corporate governance statement \n2-13 \nDelegation of responsibility for managing \nimpacts \np58 AR2023 Management report / corporate governance statement \n2-14 \nRole of the highest governance body in \nsustainability reporting \np65 AR2023 Management report / corporate governance statement / sustainability \nboard meeting \n2-15 \nConflicts of interest \np57 AR2023 Management report / corporate governance statement / conflict of \ninterest \n2-16 \nCommunication of critical concerns \np51 AR2023 Management report / principal risks and uncertainties faced by the \ncompany \np80 AR2023 Management report",
      "similarity_score": 0.07517706930329386,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1049,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "3-1 \nManagement of material topics \np34 AR2023 A committed company / employees \n405-1 \nDiversity of governance bodies and \nemployees \np66 AR2023 Management report / corporate governance statement / diversity, equity and inclusion policy \np194 AR2023 GRI appendix 405-1 / diversity of employees \n405-2 \nRatio of basic salary and remuneration of \nwomen to men \np80 AR2023 Management report / corporate governance statement / codes of \nconduct \nGRI 414 SUPPLIER SOCIAL ASSESSMENT v2016",
      "similarity_score": 0.058416437054025536,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1070,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "=== Page 139 ===\nIBA Annual Report 2023 \n136. 4.6.2 Deferred tax \n (EUR 000) \nDecember 31, 2022 \nDecember 31, 2023 \nDEFERRED TAX ASSETS \nDeferred tax assets to be recovered after 12 months Tax losses on carry-forward \n15 917 \n13 649 \nDeferred tax assets to be recovered after 12 months - Temporary differences \n426 \n400 \nDeferred tax assets to be recovered within 12 months - Tax losses on carry-forward \n0 \n0 \nDeferred tax assets to be recovered within 12 months - Temporary differences \n4 607 \n4 313 \nTOTAL \n20 950 \n18 363 \nDeferred tax liabilities netted against the deferred tax assets in the sta",
      "similarity_score": 0.05581746666444222,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 754,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "y. PET imaging is a highly effective medical imaging technique \nthat uses radiotracers to produce detailed images of organs and \ntissues in the body. It is used in the diagnosis and treatment of a \nwide range of medical conditions, including cancer, neurological \ndisorders, and cardiovascular disease. CycloneKEY is giving the opportunity \nto anyone, anywhere in the word to get \naccess to PET cyclotron technology \nand PET imaging. Its also very interesting for inhouse \nproduction because the local hospital \nwill not depend on the big suppliers \nof radio-pharmaceuticals.",
      "similarity_score": 0.05622184767487454,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 58,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "As at December 31, 2023 and December 31, 2022, there are no contract assets set as a \nwarranty to cover the financing of a proton \ntherapy contract. As at December 31, 2023, contracts in progress \nand amounts due to customers for contract \nassets showed a net position of EUR -245.0 \nmillion compared to EUR -256.8 million as at \nDecember 31, 2022. The decrease of EUR 11.8 \nmillion is primarily explained by the progress \nmade on some customer sites, despite the level \nof billings remaining high in 2023.",
      "similarity_score": 0.05917140028870943,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 718,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}